Rationale, design, and results from RENO-DEFEND 1: A randomized, dose-finding study of the selective A1 adenosine antagonist SLV320 in patients hospitalized with acute heart failure

American Heart Journal

Volumn 161, Issue 6, 2011, Pages

  Pang, Peter S ^a   Mehra, Mandeep ^b   Maggioni, Aldo P ^c   Filippatos, Gerasimos ^d   Middlebrooks, Jayne ^e   Turlapaty, Prasad ^e   Kazei, Dmitri ^e   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c ANMCO RESEARCH CENTER   (Italy)

^d NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^e ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; CYSTATIN C; PLACEBO; SLV 320; TROPONIN I; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; AGED; ANEMIA; ANGINA PECTORIS; ARTICLE; BODY WEIGHT; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; GLOMERULUS FILTRATION RATE; GOUT; HEART ATRIUM FIBRILLATION; HEART BUNDLE BRANCH BLOCK; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; INSOMNIA; KIDNEY FAILURE; LABORATORY DIAGNOSIS; MALE; MENTAL DISEASE; MITRAL VALVE REGURGITATION; MORTALITY; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION;

EID: 79958162478     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.03.004     Document Type: Article

References (13)

1. G. Filippatos, J. Rossi, and D.M. Lloyd-Jones Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study J Card Fail 13 2007 360 364 (Pubitemid 46977793)
2. L. Klein, B.M. Massie, and J.D. Leimberger Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinione for Exacerbation of Chronic Heart Failure (OPTIME-CHF) Circulation: Heart Failure 1 2008 25 33
3. K. Damman, G. Navis, and A.A. Voors Worsening renal function and prognosis in heart failure: systematic review and meta-analysis J Card Fail 13 2007 599 608 (Pubitemid 47513536)
4. G.L. Smith, J.H. Lichtman, and M.B. Bracken Renal impairment and outcomes in heart failure: systematic review and meta-analysis J Am Coll Cardiol 47 2006 1987 1996
5. M. Jessup, and M.R. Costanzo The cardiorenal syndrome: do we need a change of strategy or a change of tactics J Am Coll Cardiol 53 2009 597 599
6. V. Hasselblad, W. Gattis Stough, and M.R. Shah Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial Eur J Heart Fail 9 2007 1064 1069 (Pubitemid 47451811)
7. M.R. Costanzo, M.E. Guglin, and M.T. Saltzberg Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure J Am Coll Cardiol 49 2007 675 683 (Pubitemid 46205043)
8. M. Gheorghiade, M.A. Konstam, and J.C. Burnett Jr Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST clinical status trials JAMA 297 2007 1332 1343 (Pubitemid 46513234)
9. S.S. Gottlieb, D.C. Brater, and I. Thomas BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy Circulation 105 2002 1348 1353 (Pubitemid 34260427)
10. S.S. Gottlieb, S.L. Skettino, and A. Wolff Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure J Am Coll Cardiol 35 2000 56 59 (Pubitemid 30061259)
11. M.M. Givertz, B.M. Massie, and T.K. Fields The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance J Am Coll Cardiol 50 2007 1551 1560 (Pubitemid 47532320)
12. G. Cotter, H.C. Dittrich, and B.D. Weatherley The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment J Card Fail 14 2008 631 640
13. B.M. Massie, C.M. O'Connor, and M. Metra Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure N Engl J Med 363 2010 1419 1428